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Hirschsprung disease (HSCR) is a common congenital disorder characterized by aganglionosis of the gut. The
seemingly unrelated multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant disorder characterized
by medullary thyroid carcinoma (MTC), pheochromocytoma, and hyperparathyroidism. Yet, germline mutations
in the RET proto-oncogene are associated with both MEN 2 and HSCR. In the former, gain-of-function mutations
in a limited set of codons is found, whereas, in the latter, loss-of-function mutations are found. However, germline
RET mutation is associated with only 3% of a population-based series of isolated HSCR, and little is known about
susceptibility to sporadic MTC. We have found previously that specific haplotypes comprising RET coding single-
nucleotide polymorphisms (SNPs) comprising exon 2 SNP A45A were strongly associated with HSCR, whereas
haplotypes associated with exon 14 SNP S836S were associated with MTC. In this study, we describe three novel
intron 1 SNPs, and, together with the coding SNP haplotypes, the data suggest the presence of distinct ancestral
haplotypes for HSCR and sporadic MTC in linkage disequilibrium with a putative founding susceptibility locus/
loci. The data are consistent with the presence of a very ancient, low-penetrance founder locus ∼20–30 kb upstream
of SNP A45A, but the failure of the SNPs to span the locus presents challenges in modeling mode of transmission
or ancestry. We postulate that this founding locus is germane to both isolated HSCR and MTC but also that
different mutations in this locus would predispose to one or the other.
Introduction
Germline gain-of-function mutations of the RET proto-
oncogene, encoding a receptor tyrosine kinase on
10q11.2, cause multiple endocrine neoplasia type 2
(MEN 2 [MIM 164761]) and loss-of-function mutations
are associated with a small subset of Hirschsprung dis-
ease (HSCR [OMIM 142623]). Germline mutations in
six different exons of the RET proto-oncogene (exons
10, 11, 13, 14, 15, and 16) account for at least 92% of
cases of MEN 2, which is characterized by the triad of
medullary thyroid carcinoma (MTC), pheochromocy-
toma, and hyperparathryoidism (Eng et al. 1996a).
MEN 2, the heritable form of MTC, is believed to ac-
count for 25% of all MTC presentations. Thus, 75%
are believed to be sporadic.
The etiology of sporadic MTC is not well understood
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(for review, see Eng 1999). Limited somatic genetic al-
terations—such as loss of heterozygosity of markers and
somatic mutations in RET, principally M918T—have
been described in sporadic MTC (Mulligan et al. 1993;
Eng et al. 1994, 1995, 1996b; Hofstra et al. 1994) (re-
viewed in Eng 1999). Recently, we reported an over-
representation of a germline RET sequence variant in
exon 14, S836S (c.2439 CrT), among isolated patients
from Germany affected with MTC, compared with a
control population with the same geographic origin and
ethnic and genetic backgrounds (Gimm et al. 1999). The
association of S836S with MTC was confirmed, inde-
pendently, in another series of European patients with
MTC (Ruiz et al. 2001). These observations suggest that
the phenomenon of association of S836S with MTC
could be universal and that there is an ancestral low-
penetrance susceptibility marker for MTC within the
RET proto-oncogene (Ruiz et al. 2001). To date, S836S
is the only germline susceptibility factor that has been
identified for sporadic medullary thyroid cancer. Al-
though various hypotheses have been suggested for its
molecular mechanism, this remains unknown at this
time (Gimm et al. 1999; Ruiz et al. 2001).
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HSCR or aganglionic megacolon is a common dis-
order, occurring in 1 in 5,000 live births characterized
by the absence of the intramural ganglia of Meissner
and Auerbach in the hindgut and resulting in functional
intestinal obstruction. HSCR most commonly presents
in isolated cases, although it can be familial and may
be inherited as autosomal dominant or autosomal re-
cessive, with reduced penetrance and male predomi-
nance (Badner et al. 1990; Passarge 1967). The RET
proto-oncogene is considered a major susceptibility
gene for HSCR (Lyonnet et al. 1993; Edery et al. 1994;
Romeo et al. 1994; Chakravarti 1996). Depending on
the referral series, up to 50% of familial HSCR cases
and anywhere between 10% and 35% of sporadic cases
were reported to be accounted for by loss-of-function
germline RET mutations (Angrist et al. 1995; Attie´ et
al. 1995; Eng 1996). The only population-based series,
however, estimates the frequency of germline RET mu-
tation in 69 unselected patients with HSCR to be 7%,
and only 3% of isolated patients with HSCR in this
population-based series had traditional germline RET
mutations (Svensson et al. 1998). Several other putative
HSCR susceptibility genes have been proposed for syn-
dromic and nonsyndromic HSCR (Puffenberger et al.
1995; Angrist et al. 1996; Amiel et al. 1996, 2001;
Auricchio et al. 1996; Edery et al. 1996; Bidaud et al.
1997; Doray et al. 1998; Pingault et al. 1998; Southard-
Smith et al. 1998; Wakamatsu et al. 2001).
The molecular mechanism responsible for the major-
ity of isolated patients with HSCR remains unknown.
It has been suggested that the sporadic cases of HSCR
might be accounted for by a model of polygenic inher-
itance (Bolk et al. 2000). We have found a significant
over-representation of the RET A45A (nt c135GrA,
exon 2) and L769L (nt c2307TrG, exon 13) intragenic
sequence variants in our cohort of patients with spo-
radic HSCR compared to the control group (P !
) (Borrego et al. 1999). These findings were in-.0006
dependently confirmed in a HSCR cohort of German
origin (Fitze et al. 1999). It was proposed that the A45A
and L769L polymorphisms could act as low-penetrance
alleles and/or as factors modifying the phenotypic ex-
pression or even be in linkage disequilibrium with an
unknown functional variant (Borrego et al. 1998, 1999,
2000; Fitze et al. 1999). We subsequently studied the
haplotypes on the basis of the combination of the seven
polymorphic variants in the RET coding region. The
over-represented haplotypes in HSCR were the so-called
haplotype B (which includes only the A45A polymor-
phism) and haplotype C (which includes A45A and
L769L). Analysis of phase-known genotypes (i.e.,
paired haplotypes) indicated an over-representation of
genotypes BB, BC, and CC in the HSCR series versus
the control group. On the basis of these data, it was
proposed that the association of these genotypes with
HSCR susceptibility occurs in an autosomal recessive
manner in an additive dose-dependent manner (Borrego
et al. 2000).
The existing data for HSCR suggest one of two hy-
potheses. Either the sequence variation representing
each of the “at risk” haplotypes is itself functional and
leads to low-penetrance loss of function, or the “at risk”
haplotypes represent linkage disequilibrium with the ac-
tual low-penetrance susceptibility locus. There also ap-
pear to be consistent haplotypes containing S836S in
patients with MTC, and the same two hypotheses hold
as with HSCR: either the variant is functional, or these
haplotypes are in linkage disequilibrium with a low-
penetrance susceptibility locus. Because the haplotypes
containing S836S in sporadic MTC never coincide with
the HSCR “risk” haplotypes, we might postulate the
existence of a single modifying/regulating locus of RET
function where different specific alterations lead to op-
posing functional effects, conferring specific suscepti-
bility to either MTC or HSCR. To begin testing these
hypotheses, we sought to identify and characterize novel
SNPs upstream of the earlier examined haplotypes and
to use all of the data in haplotype analyses.
Material and Methods
Patients and Control Subjects
In the present work, we have included 103 patients
affected with clinically sporadic HSCR, their unaffected
parents, 51 patients affected with sporadic MTC, and
100 normal control subjects. Traditional germline MEN
2–defining RET mutations are absent in the 51 patients
with sporadic MTC. HSCR and MTC cohorts have been
described in our previous publications (Borrego et al.
1999, 2000; Ruiz et al. 2001). Normal control subjects
were unselected, unrelated race-, age-, and gender-
matched individuals from Spain. Informed consent was
obtained in accordance with the approved protocols of
the respective institutional review boards for the pro-
tection of human subjects.
Sequence Analysis of Intron 1 of RET
Genomic DNA was obtained from peripheral blood
leukocytes using standard protocols (Dracopoli et al.
1994). To meticulously search for new SNPs within in-
tron 1 of the RET proto-oncogene, we performed en-
zymatic mutation detection (EMD), beginning from 3′
of the intron, on overlapping fragments of 300 bp to 1
kb in length, according to the manufacturer’s recom-
mendations (del Tito et al. 1998) (fig. 1A and table 1).
When any putative DNA variant was detected, we pro-
ceeded to direct sequencing of the fragments, by use of
conditions published elsewhere (Marcos et al. 2000), to
characterize the changes observed.
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Figure 1 Characterization of novel SNPs in RET intron 1. A, Schematic representation on 3′ end of intron 1 of the RET proto-oncogene.
Codon 45 and the 3 IVS1 SNPs are indicated. B, left panel, genotyping of IVS1-126GrT by fluorescent SSCP. Lanes 1, 2, 5, 6, and 11–14,
genotype /. Lanes 3, 4, and 7–10, genotype /. Lanes 15 and 16, genotype /. Right panel, genotyping of IVS1-126GrT by differential
restriction with NlaIII. Lane 2, a nondigested sample. Lane 3, genotype /. Lanes 4 and 5, genotype /. Lane 6, genotype /. C, FRET
analysis of IVS1-1370CrT and IVS1-1463TrC. In each case, amplicons containing the polymorphisms have a melting point (MP) which is
19C lower (in the case of IVS1-1370CrT) and 3C higher (in the case of IVS1-1463TrC) than the amplicons with the wild-type sequence.
Genotype / , /, and / are represented in red, blue, and green, respectively.
Genotyping of SNPs
The variant IVS1-126GrT was genotyped using fluo-
rescent SSCP analysis, after digestion of the PCR product
with MspI (Roche), under conditions described else-
where (Marcos et al. 2000). In addition, the results were
confirmed by differential restriction digestion with
NlaIII (New England Biolabs), since this enzyme loses a
restriction site in the presence of the variant (fig. 1B).
To detect IVS1-1370CrT and IVS1-1463TrC, we
have developed an automated method using fluorescence
resonance energy transfer (FRET) technology. Internal
probes were designed according to the sequences of in-
terest and were purchased from TIB Molbiol. The whole
procedure, including real-time PCR and a melting curve,
was performed in a LightCycler machine (Roche) (fig.
1C and table 2).
Phase of haplotypes was determined by typing of the
corresponding parents of patients with HSCR and con-
trol subjects where available (86% of patients with
HSCR and 65% of control subjects had parents avail-
able for typing [data not shown]). Haplotypes (i.e.,
phase) were similar in patients and control subjects, and,
thus, haplotypes from patients with MTC were inferred
from the haplotypes available in patients with HSCR
and control subjects. The median age of sporadic MTC
diagnosis is 55–60 years, and, hence, the parents of pa-
tients with MTC were, in general, deceased.
Statistical Analysis
Allelic frequencies of the three new RET polymorphic
loci were determined, and haplotypes were constructed
(tables 3 and 4). The frequencies of each haplotype were
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Table 1
PCR Conditions of Individual Fragments within Intron 1 of RET Proto-Oncogene
FRAGMENT
PRIMERS
(5′r3′)
SIZE
(bp)
ANNEALING
TEMPERATURE
(C ) CYCLESForward Reverse
P1 M13F*-GTGGAAGTTGTGGTGAGCCAAG M13R*-GTGGGAAGTAGGGAAGTGAGTGAG 1,057 67 35
P13 M13F-TGGCACAATCTCGGCTCACTAC M13R-CTTGGCTCACCACAACTTCCAC 1,051 68 35
P1b M13F-ATGACTTTCCTGTAAAGTGC M13R-GGAGTTTTTCATCTCTGTTC 338 54 35
P1a M13F-AGATAAGATGCACGGACCTTAG M13R-GCAACAGTTGCCAAAAAATG 596 60 35
P13b M13F-CCAGAAGTGGGATTGGTAG M13R-TCACCACAACTTCCACCTC 597 59 35
P13a M13F-GTGCAATGGCACAATCTC M13R-GAAAAACAAGAAGGTAGTTCCC 552 58 35
NOTE.—Primers were designed using the PRIME command of GCG-Wisconsin software, and all of them had universal M13 primers attached at the
5′ ends. M13F*: CGCCAGGGTTTTCCCAGTCACGAC; M13R*: TTTCACACAGGAAACAGCTATGAC. Fragments P1 and P13 were each divided into
two smaller fragments (a and b), to obtain better results in the performance of EMD technology. Fragments were overlapping, except for P1a and P13b,
which were separated by the STR (TAAAn).
compared between the patients with MTC and control
subjects, as well as between patients with HSCR and
control subjects and between patients with MTC and
patients with HSCR. Comparisons were performed us-
ing either x2 analysis with Yates’s correction or, when
appropriate, Fisher’s two-tailed exact test. Nominal sta-
tistical significance was considered when .P ! .05
Haplotype analyses were performed by reconstructing
and comparing the transmitted versus nontransmitted
haplotypes to patients with HSCR, with the understand-
ing that meiotic recombination is negligible for a single
generation across such a short region. This approach is
consistent with the haplotype relative risk approach of
Falk and Rubinstein (1987) and is largely robust to pop-
ulation stratification (described by Ott [1999], p. 293).
Full multipoint model-based analyses of a founding
locus were performed using DMLE (Reeve and Ran-
nala 2002), which uses Monte Carlo integration to ap-
proximate Bayesian posteriors for locus position and
age. Calculations were performed on a Pentium 4 work-
station, using recommended burn-in and sampling in-
tervals and a variety of modeling assumptions and pa-
rameter ranges, including population growth rates. The
composite likelihood ratio of DISMULT (Terwilliger
1995) was also computed, using a Unix workstation.
Numerical difficulties in evaluating the likelihood over
such short intervals was resolved by artificially inflating
the map distances, while interpreting the mutation age
as increased by the same proportion.
In addition to these approaches, simple haplotype
methods were used to test against the null hypothesis of
equal transmission probabilities. These included speci-
fication of putative ancestral haplotypes and permuta-
tion testing by drawing 10,000 random permutations of
the transmission status of all haplotypes. For each per-
mutation, the maximum nominal x2 statistic was re-
corded in the association of each haplotype (vs. all others
combined) with transmission status. A somewhat more
structured approach is described below.
The degree of linkage disequilibrium between disease
and a marker locus is often described as pexcess, which
measures the proportion of alleles at a locus caused by
the putative founding mutation (de la Chapelle and
Wright 1998). If an allele is associated with disease (e.g.,
the polymorphic allele A at codon 45 (Borrego et al.
1999, 2000), then we can compare the proportion of
transmitted chromosomes which have the allele (paffected)
with the proportion in nontransmitted chromosomes
(pnormal). From these, we can compute p pexcess
.(p  p )/(1 p )affected normal normal
If there is a predominant ancestral haplotype, then the
value of pexcess will tend to reach a maximum at markers
very near the mutation and to descend as one moves
away from the mutation. Moreover, the maximum value
of pexcess (attained at the mutation locus) represents the
proportion of transmitted chromosomes that contain the
ancestral mutation. For a rare recessive disease, this can
be, at most, 1, and for a rare dominant disease, it can
be, at most, 0.5. The estimate of pexcess at A45A is ∼0.45
(derived from the frequency estimates of Borrego et al.
[1999]), which suggests that, if the mutation exists, it is
responsible for a large portion of sporadic HSCR in this
population. Often, pexcess will not achieve the theoretical
maximum value because of the presence of additional
founding mutations that account for some of the spo-
radic cases.
To generalize this approach to multiple markers, we
used a method (Gao and Wright 1999) that examines
haplotypes in varying window widths of successive SNPs
to find the window in which haplotypes (all treated sep-
arately) are most strikingly associated with disease, as
judged by a x2 statistic. The null distribution of this
maximal statistic can be generated by recomputing it
over permutation samples of transmission status. Also,
we recorded, for each SNP, the single haplotype (over
all window widths) most associated with transmission,
which was then treated as if it were a single allele in a
pexcess plot. The result is a plot of so-called hexcess (similar
to pexcess, but with less error variation) for the excess of
the haplotype among transmitted chromosomes as a
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Table 2
FRET Conditions for Detection of the Polymorphisms within Intron 1 of RET Proto-Oncogene
POLYMORPHISM
GENOTYPED PROBESa
MELTING CONDITIONS AFTER AMPLIFICATION
Temperature
Transition
(C)
Transition
Rate
(C/s) Gains (F1:F2:F3)
IVS1-1370CrT Anchor: 5′- YgCTCACTCAgCCACAgCCgAggC p
Sensor: 5′- TgCACCgTgCCCCTgCTTg X
From 50 to 95 .40
1:45:30
IVS1-1463TrC Anchor: 5′- TTTTTgggAACTACCTTCTTgTTTTTCAT
Sensor: 5′- Y-ACTgTATATTATTTTCCACTCACCgA p
From 40 to 95 .20
NOTE.—We used 50 cycles of PCR at an annealing temperature of 66C.
a Boldface italics denote the nucleotides that are sensitive for the wild-type or the polymorphic allele. “X” represents fluorescein,
and “Y” represents LC-Red 640. Some probes have modifications (represented by “p”) in their 3′ that disable extension of Taq
polymerase.
function of physical position, and it is similar to the
multiple-SNP haplotype-based disequilibrium measure
described by Daly et al. (2001). Under the assumption
that the ancestral haplotype has been correctly identified,
hexcess at the mutation also represents the proportion of
transmitted chromosomes containing the mutation.
Finally, noting that expected linkage disequilibrium
decays exponentially with increasing recombination
fraction (see, e.g, Hastbacka et al. 1992), simple linear
regression of log(hexcess) on genomic position was per-
formed, under the assumption that all transmitted chro-
mosomes contain the ancestral mutation. This simple
moment-based approach is based on our method for
testing against a null hypothesis, but with no specifi-
cation of the complicated dependencies arising under the
alternative. Thus, it does not naturally give rise to CIs
or precise inferential statements about the mutation age
or location.
Results
Identification of Three Novel RET Intron 1 SNPs
Using a series of bioinformatics manipulations within
GenBank and the National Center for Biotechnology
Information (NCBI), we uncovered a 505-kb genomic
contig on 10q23 that contained the entire RET sequence
(GenBank accession number AC010864 [subfile of
NT_033987]). Using the Blast 2 sequences tool at the
NCBI Web site, we aligned the AC010864 sequence with
those of exons 1 and 2 of the RET proto-oncogene de-
scribed earlier. The result was a segment of contig
AC010864 that contained the complete sequence of in-
tron 1 of RET (23,127 bp). We were able to identify
three novel SNPs within intron 1: IVS1-126 GrT, IVS1-
1370 CrT, and IVS1-1463 TrC (fig. 1).
Studies of Association Between the Three Intron 1
SNPs and HSCR or MTC
Patients with HSCR versus control subjects.—The
three newly identified intron 1 SNPs were found to be
under-represented in the HSCR cohort compared to the
control population (table 3). For example, of a total of
206 HSCR chromosomes, there were 44 chromosomes
(21%) with the T variant at the IVS1-126GrT locus,
and 162 (79%) the wild-type G allele. The T variant
was significantly under-represented when compared to
the control series (x2 with Yates’s correction 8.69,
). Similarly, the IVS1-1370CrT and IVS1-Pp .0032
1463TrC polymorphic alleles (T and C, respectively)
were also under-represented in the HSCR cohort com-
pared to those observed in the control group (table 3;
).P K .000001
Patients with MTC versus control subjects.—In con-
trast to the HSCR cohort, the IVS1-126GrT polymor-
phic allele was over-represented in patients with sporadic
MTC. Of 102 MTC chromosomes studied, 49 (48%)
carried the polymorphic T allele, and 53 (52%) carried
the wild-type G ( ; with Yates’s cor-2x p 4.28 Pp .038
rection) (table 3). We did not find any statistically sig-
nificant differences when comparing the allelic frequen-
cies of the IVS1-1370CrT and IVS1-1463TrC loci
between MTC and control subjects (table 3).
Patients with HSCR versus patients with MTC.—One
highlight of the results obtained in the analysis of allele
frequencies of the newly identified loci was the inversion
in the frequency of IVS1-126GrT when comparing the
series of patients with MTC to the HSCR series. The
frequency observed for this marker in the control pop-
ulation appeared in a range intermediate between those
observed in patients of both pathologies (T: 70 [35%];
G: 130 [65%]). In comparison of the allele distribution
of the SNPs between cohorts (HSCR vs. MTC), it was
remarkable to note an inversion of the allele frequencies
for each genotyped marker (tables 3 and 4).
Haplotype Analysis Using Intron 1 SNPs: Evidence of
Association of Haplotype 0 and HSCR, and Haplotype
2 with MTC
Using the information on the segregation of the SNPs
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Table 3
Comparative Studies between the Groups, using x2 Analysis with Yates’s Correction
RESULTS OF COMPARISON
HSCR vs. Control sMTC vs. Control sMTC vs. HSCR
HSCR Alleles Control Alleles sMTC Alleles Control Alleles sMTC Alleles HSCR Alleles
IVS1-126GrT:
No. of polymorphic T alleles 44 70 49 70 49 44
No. of wild-type G alleles 162 130 53 130 53 162
x2 with Yates’s correction (P value) 8.69 ( )Pp .0032053 .28 ( )Pp .0385776 21.79 ( )Pp .000003
IVS1-1370CrT:
No. of polymorphic T alleles 39 94 40 94 40 39
No. of wild-type C alleles 167 106 62 106 62 167
x2 with Yates’s correction (P value) 35.03 ( )P ! .000001 1.36 ( )Pp .2438972 13.67 ( )Pp .0002175
IVS1-1463TrC:
No. of polymorphic C alleles 84 163 89 163 89 84
No. of wild-type T alleles 122 37 13 37 13 122
x2 with Yates’s correction (P value) 68.94 ( )P ! .000001 1.23 ( )Pp .2674883 57.99 ( )P ! .000001
Table 4
Polymorphic Frequencies in Patients with sMTC,
Control Subjects, and Patients with HSCR
ALLELE
FREQUENCY IN
Patients
with
sMTC
Control
Subjects
Patients
with
HSCR
IVS1-126GrT:
Polymorphic T .48 .35 .21
Wild-type G .52 .65 .79
IVS1-1370CrT:
Polymorphic T .39 .47 .21
Wild-type C .61 .53 .79
IVS1-1463TrC:
Polymorphic C .9 .82 .41
Wild-type T .1 .18 .59
identified in HSCR patients and their parents, we per-
formed a construction of haplotypes comprising differ-
ent combinations of the three SNPs at the 3′ end of RET
intron 1 (table 5). The method and the group of patients
used for the haplotype construction was similar to that
described elsewhere (Borrego et al. 2000). We found a
total of five haplotypes in the patients with HSCR and
their parents (haplotypes 0–4). As the recombination
events between the markers under study were predicted
to be extremely rare (distance between SNPs !1,200 bp),
we considered each haplotype as an individual allele
within the same locus (3′ intron 1,RET proto-oncogene).
Parents of MTC or control subjects were not available,
so the haplotype construction in both groups was in-
ferred from the haplotype of the HSCR patients. The
haplotype distribution observed in the MTC, control,
and HSCR groups was different. Thus, haplotype dis-
tribution of each cohort compared to the control group
(MTC vs. control subjects or HSCR vs. control subjects),
was found to be statistically significant ( ) (fig.P ! .0023
3).
We verified that haplotype 0 was the most common
in the HSCR group (59%) (fig. 3). It is important to
note that haplotype 0 is in complete linkage disequilib-
rium with all the risk haplotypes described so far (Bor-
rego et al. 1999, 2000). That is, all the risk haplotypes
share the same sequence of SNPs in this genomic segment
of intron 1 (haplotype 0). This is consistent with our
studies of linkage disequilibrium mapping and would
place the locus of susceptibility to HSCR at ∼20 kb from
the A45A marker (see below as well).
Haplotype 2 is the most frequent in patients with spo-
radic MTC (48%) (haplotype that contains IVS1-
126GrT and IVS1-1463TrC in disequilibrium), whereas
the frequency of haplotype 0 is notably low (12.7%). The
MTC patients that carry S836S also carry intron 1 hap-
lotype 2, which suggests that S836S and haplotype 2 are
in linkage disequilibrium. These data have been confirmed
in three patients with MTC who were homozygous for
haplotype 2 and heterozygous for S836S.
The haplotypes observed in the control series show a
distribution intermediate to that observed in the MTC
and HSCR cohorts. Haplotype 1 was the most common
in the control subjects (43%). Furthermore, haplotype
4, which is not represented in any of the patient series
being studied, appears with a certain frequency (4%).
Haplotype 0 has a frequency of 18.5% in control sub-
jects, compared with 59% in patients with HSCR and
12.7% in patients with MTC. The frequency of hap-
lotype 2 in control subjects was 31%, compared with
21.3% in individuals with HSCR and 48% in individ-
uals with MTC. These observations suggest that hap-
lotype 0 could be a haplotype associated with HSCR,
and haplotype 2, a haplotype associated with MTC (fig.
3; also see below).
Analysis of the IVS1 Genotypes in HSCR and MTC
We studied the genotype composition (pairs of hap-
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Table 5
Haplotypes Based in the Combination of Three SNPs Located
within Intron 1 of RET
HAPLOTYPE
PRESENCE/ABSENCE OF
IVS1-126GrT IVS1-1370CrT IVS1-1463TrC
0   
1   
2   
3   
4   
NOTE.— p present;  p absent.
lotypes) in each study group (fig. 3). Genotypes 00 and
02 predominate in HSCR (70%), whereas, in MTC, ge-
notypes 12 and 22 are more predominant (67%). In the
control group, the most common genotype was 12, fol-
lowed by 11 and 22. Analysis of the genotypes observed/
expected in the study groups shows that the results are
in Hardy-Weinberg equilibrium. If we compare the dis-
tribution of genotypes between both study groups (MTC
and HSCR), the deviation is rather striking (fig. 3). As
a whole, these findings corroborate the observations
made in individual allele as well as haplotype frequency
studies.
Haplotype Analysis Using All 10 RET SNPs: Evidence
for a Novel Founding Locus for HSCR
Using the data from the same consecutive incident
cases of isolated HSCR from the Western Andalusia re-
gion described in Borrego et al. (1999, 2000), we have
analyzed the observed RET haplotypes and their asso-
ciation with HSCR for evidence of a mutation or variant
contributing to sporadic cases of disease. This offers a
potentially more parsimonious explanation for the link-
age disequilibrium than the hypothesis that the poly-
morphisms in RET have subtle functional effects.
We analyzed the transmitted versus nontransmitted
haplotypes using DMLE (see the “Material and Meth-
ods” section), which is a fully model-based approach for
linkage disequilibrium mapping. The results were diffi-
cult to interpret, as the posterior for mutation location
was extremely short (!1% of allowed range) and always
placed at the extreme 5′ end of the allowed range. Mu-
tation age estimates were very highly sensitive to starting
values, despite long burn-in times for DMLE and
ranged from 200 to 1,500 generations, under the as-
sumption of an average correspondence of 1 cM p 1
Mb. We speculate that the difficulty in obtaining esti-
mates stems from the failure of the SNPs to span the
mutation, in contrast to classic examples used to eval-
uate the approach (e.g., diastrophic dysplasia [Reeve and
Rannala 2002]). The program DISMULT achieved max-
imum-likelihood values at or just upstream of the most
5′ SNP IVS1-1463, with estimated mutation age (see the
“Material and Methods” section) sharply changing from
4,100 to 8,000 generations in a short interval having
high likelihood, and with estimated proportion of the
mutation, among transmitted chromosomes, of ∼0.45.
Our haplotype-based linkage-disequilibrium analysis
is in rough agreement with the DISMULT results, except
that we believe the data do not preclude the possibility
that a mutation may exist further upstream of the de-
scribe RET polymorphisms (5′ direction, centromeric).
The hexcess plot in figure 2 (see the “Materials and
Methods” section) is maximized at ∼0.45, at the most
5′ SNPs, and reveals that the linkage disequilibrium de-
scends toward the 3′ end of RET. The permutation-based
empirical P value for the association of ancestral hap-
lotype with transmission status was !.0001. The fact
that the linkage disequilibrium levels off for a few mark-
ers at a time is expected—this reflects that historical
crossovers occurred at only a few points across RET.
Most compelling is the fact that the “most significant”
short haplotypes at each marker position (i.e., in x2 tests
of association with disease) are consistent with a single,
longer ancestral haplotype. The ancestral haplotype for
the 10 SNPs appears to be (5′r3′) WWWMWW-
WMWW, where M signifies mutant and W wild type.
This is haplotype C from the Borrego et al. (2000) study,
with the addition of the three new SNPs from intron 1.
Haplotype MWMWMWWWWW is associated with
disease (9 transmitted vs. 0 nontransmitted) but may be
part of a different minor founding mutation.
The maximum value that the linkage-disequilibrium
measure attains is not known and awaits further deter-
mination of SNPs in intron 1 and upstream of RET. An
exponential fit to the decaying linkage-disequilibrium
measure (which cannot exceed 1.0) in figure 2 (dashed
line) suggests that the major mutation is likely to reside
in intron 1 or just upstream of RET.
A recent refined genetic map indicates that the rate of
recombination per unit of physical distance in the vicin-
ity of RET is ∼0.8 cM/Mb (Kong et al. 2002). Com-
bining this information with the fitted rate of decay re-
sults in an estimated time from the founding mutation
of 3,800 generations. Such a surprisingly ancient esti-
mate must be interpreted with caution, as the recom-
bination rate and mutation age are confounded, and the
resolution of such recombination rate estimates remains
low. Moreover, although linkage disequilibrium is
clearly present, the current data do not support the con-
struction of plausible CIs. Nonetheless, the data are con-
sistent with a founder mutation old enough to be wide-
spread in European populations. This is further sup-
ported by the report from Fitze et al. (1999), in which
genotypes of the same seven polymorphisms studied ear-
lier by us (Borrego et al. 2000) display a very similar
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Figure 2 Excess proportion of ancestral haplotypes among transmitted chromosomes to HSCR patients (see text). The fitted line of
expected linkage disequilibrium suggests that the ancestral mutation lies in or near the 5′ region of RET—that is, within intron 1. A schematic
of partial RET gene structure on which the positions of the 10 SNPs are placed lies below the plot. Numbers on top of the gene schematic are
exon numbers, and the codes below represent the nature and position of the SNPs.
pattern of association with sporadic HSCR in a German
population.
Discussion
Traditional germline mutations identified in the RET
proto-oncogene have been associated with two different
neurocristopathies (MEN 2 and HSCR). The phenotype
observed in one is completely different from that in the
other (for a review, see MIM 142623 and MIM 164761),
and the molecular mechanism proposed for the two cases
seem to be opposites, according to the available func-
tional data. Mutations causing MEN 2 produce gain-
of-function alterations in the cascade of RET signals,
either because of constitutive activation or alteration of
substrate specificity (Santoro et al. 1990; Songyang et
al. 1995). In patients with HSCR, traditional RET mu-
tations typically result in loss of function, including
structural and functional haploinsufficiency and a deficit
in the cascade of RET signals in the target tissues (Pasini
et al. 1995; Pelet et al. 1998). It has recently been pro-
posed that the mechanism of some HSCR mutations
could consist of an activation of cryptic proapoptotic
functional motifs in the altered RET protein that lead
to premature apoptosis (Bordeaux et al. 2000). The ob-
servation that the RET receptor is involved both in tu-
morigenesis and in the development of the nervous sys-
tem is reminiscent of that observed for the p75NTR and
Figure 3 Comparison of the frequencies and distribution of RET IVS1 haplotypes and genotypes between HSCR or patients with MTC and control subjects. x2 (Yates’s correction) and P values
are denoted below each comparison.
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DCC receptors, in which the proapoptosis mechanism
seems similar to that observed in both cases (Rabizdeh
et al. 1993; Mehlen et al. 1998).
In contrast to the traditional mutations described for
a subset of HSCR and the majority of MEN 2, the
isolated forms of both pathologies—namely, MTC and
HSCR—appear to be attributable to low-penetrance al-
leles, the downstream functional mechanism of which
is unknown. These alleles have been identified using
common polymorphisms throughout the RET proto-
oncogene sequence and studying genetic association or
disequilibrium of transmission in families affected with
HSCR with incomplete penetrance (Borrego et al. 1998,
1999, 2000; Fitze et al. 1999; Gimm et al. 1999; Bolk
et al. 2000; Griseri et al. 2000). Initially, direct action
mechanisms of the linked coding RET coding SNPs,
such as the activation of cryptic splicing sites or altered
expression of the allele with the variant (producing over-
or underexpression of the RET proto-oncogene) were
proposed. As an alternative, the mechanism was also
suggested to be the preferential use of specific tRNAs
that reduced the efficiency of the translation of the allele
that carried the variant, and the alteration of functional
motifs of the RET sequence which constituted the tar-
gets for DNA- or RNA-binding proteins. Although
some functional studies have been performed on these
polymorphisms, no alteration has yet been described
that explains the direct effect of any of the SNPs as-
sociated with both pathologies (Griseri et al. 2000).
Besides the hypothesis of direct action of the markers
linked to each pathology, a mechanism related to the
existence of linkage disequilibrium of some functional
allele in noncoding sequence with the markers studied
has also been considered (Borrego et al. 1998, 1999,
2000; Fitze et al. 1999; Gimm et al. 1999; Bolk et al.
2000; Griseri et al. 2000).
Together with our previous observations (Borrego et
al. 1999, 2000), our current observations indicate that
the A45A polymorphism, irrespective of the 3′ haplo-
type, is in linkage disequilibrium with a group of mark-
ers within intron 1 of the RET proto-oncogene (hap-
lotype 0-A45A). In other words, the under-repre-
sentation of the variant alleles at all three new loci
within intron 1 described in the HSCR cohort can be
explained by the polymorphic variant at codon 45
(A45A, nt c135GrA) to be in complete linkage dis-
equilibrium with the wild-type allele (G) at IVS1-
126GrT, the wild-type allele (C) at IVS1-1370CrT and
the wild-type allele (T) at IVS1-1463TrC. More im-
portantly, our statistical analysis of all 10 RET SNPs
in HSCR (see the last subsection under “Results”)
strongly suggest the existence of a low-penetrance locus
of susceptibility for HSCR at a distance of !20 kb from
RET codon 45, perhaps still within intron 1.
In contrast to isolated HSCR, individuals with spo-
radic MTC, originating in Germany and Spain, were
shown to have an over-representation of S836S (Gimm
et al. 1999; Ruiz et al. 2001). Similarly, the same marker
has been attributed with a protector effect against the
appearance of the HSCR phenotype (Griseri et al. 2000,
2002). Whether the sequence variation in and of itself
conferred a subtle effect on protein expression, splicing,
or function remains to be elucidated. Like the associ-
ation of specific RET haplotypes with isolated HSCR,
the existence of a functional locus in linkage disequi-
librium with S836S has also been suggested as an al-
ternative to the hypothesis of the direct effect of S836S
(Gimm et al. 1999; Griseri et al. 2000, 2002; Ruiz et
al. 2001). This latter hypothesis and those that invoke
expressional variation are not mutually exclusive, as the
function of the linked upstream putative susceptibility
locus has yet to be elucidated. Thus, our current ob-
servations shed some light to differentiate amongst these
hypotheses. We have noted that there is a MTC-specific
risk haplotype within intron 1: haplotype 2, which is
always associated with S836S, and both haplotype 2
and S836S are concurrently over-represented among our
isolated MTC series. Our current data, therefore,
strongly suggest that the association of S836S with
MTC can be most plausibly explained by linkage dis-
equilibrium between S836S and haplotype 2. Further,
preliminary germline intron 1 haplotyping data in the
MTC cohort of German origin show a high frequency
of homozygosity for haplotype 2 (data not shown). This
suggests the existence of a low-penetrance susceptibility
locus for MTC in close proximity to that for isolated
HSCR, within intron 1 of the RET proto-oncogene.
It is tempting to speculate about the nature of the
susceptibility loci that could be located within the im-
mense intron 1 of the RET proto-oncogene. Perhaps the
most plausible hypothesis would be the existence of two
independent mutations within the same functional mo-
tif—unknown at present—that would control the tran-
scriptional activity of the RET proto-oncogene. Little
is known about the transcriptional factors that bind to
the putative RET promoter. For example, there is in
vitro evidence that RAF-1, PAX3, SOX10, AP1, and
AP2 could act as transcriptional factors that bind up-
stream of exon 1 (Carson et al. 1995; Capes-Davis et
al. 1999; Lang et al. 2000). Using the MatInspector
program (Quandt et al. 1995), bioinformatic analysis
of the region harboring the three novel SNPs predicts
four motifs that could be binding sites for transcription
factors BRN2, NFAT, IRF1, and IRF2 at IVS1-1463T
(wild type; HSCR-associated). When IVS1-1463 is al-
tered to the polymorphic C (which is MTC-associated),
the BRN2 site is obliterated and a new site for OCT1
appears. Furthermore, the two IRF sites are strength-
ened, whereas the NFAT site is weakened, in the pres-
ence of the variant. Similarly, this program also predicts
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that when the sequence is wild-type (G, HSCR-associ-
ated) at IVS1-126, there is the motif for a TCF1-binding
site. When this sequence is variant, T (MTC-associated),
an NFAT motif is created. It is interesting there is no
difference at IVS1-1370 (both wild type) between hap-
lotypes 0 (HSCR) and 2 (MTC), and no binding motifs
are predicted at this site. Unfortunately, no in vitro or
in vivo data exist regarding the plausibility of these
binding motifs and actual binding sites within RET in-
tron 1. To date, such bioinformatic mining for tran-
scription binding sites has yet to yield functionally sig-
nificant motifs for any gene in vivo. Therefore, further
experimental work is required to prove the functional
significance of these transcription factor binding sites
predicted from bioinformatic analysis.
In summary, our data demonstrate that isolated MTC
and HSCR are significantly associated with specific
linked haplotypes (haplotypes 2 and 0, respectively)
within RET intron 1. We believe that the data strongly
suggest that each haplotype is likely to be in linkage
disequilibrium with its respective putative low-pene-
trance susceptibility locus and that both loci may reside
in a very small genomic segment (!30 kb). These loci
might not only act in and of themselves as low-pene-
trance susceptibility loci for HSCR or MTC but would
likely interact with other variants and with traditional
germline HSCR-associated or MEN 2-associated mu-
tations to modulate development of features, age at on-
set, and the like, as suggested by our prior, preliminary
observations (Borrego et al. 1998).
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